



RBCs = ERYTHROCYTES




Function: facilitate transport of respiratory gases between lungs and cells

RBC SHAPE and DIMENSIONS

“biconcave” disk




ADVANTAGE of SHAPE




1. Maximal surface area and minimal diffusion distance for its volume (increases efficiency of O_2 & CO_2 diffusion)

2. High degree of flexibility
(Allows cells to squeeze through narrow capillaries)

RBC STRUCTURE and NUMBERS



5.1 – 5.5 x
 $10^6/\mu\text{L}$



4.5 - 4.8 x
 $10^6/\mu\text{L}$

($25 \times 10^{12} / 5\text{L}$)


NOTE: No Subcellular Organelles

RBCs have important Enzyme Systems:


GLYCOLYTIC ENZYMES → **Generate Energy**

CARBONIC ANHYDRASE → **CO₂ Transport**

RBC Composition




HEMOGLOBIN STRUCTURE p454¹²; 470-71¹³ Vander



200-300 x 10⁶
molecules/RBC

MW = 64K



In lungs, Hb becomes saturated with O₂ – (appears bright red)

In tissues, O₂ dissociates from Hb, (appears dark red)

HEMOGLOBIN FUNCTIONS p 462¹²; p467¹³ Vander

Solubility of O_2 in plasma is very low:

0.3 ml O_2 /100 ml plasma

In blood (because of **Hb**), carrying capacity is:

20 ml O_2 /100 ml blood

Hb FUNCTIONS

1. Transport of O₂



2. Transport of CO₂

3. Act as a buffer


What are advantages of having Hb inside the cell (rather than dissolved in plasma)?

(i) re Plasma Viscosity


(ii) re Plasma C.O.P.

(i) re Loss via Kidney

HEMOGLOBIN VALUES



16 g/100 ml blood



14 g/100 ml blood

When **Hb** is fully saturated with O_2 , each g of **Hb** holds **1.34 ml O_2**

Therefore, the O_2 carrying capacity of blood is **$15 \times 1.34 = 20 \text{ ml } O_2 / 100 \text{ ml blood}$**

Factors affecting ability of **Hb** to bind and release O_2

1. Temperature

2. Ionic Composition

3. pH

4. pCO_2

5. Intracellular enzyme concentration


ERYTHROPOIESIS

1. WHERE?

2. HOW?


3. REGULATION?

SITES of HEMATOPOIESIS




Flat bones of skull, shoulder blades, pelvis, vertebrae, sternum, ribs, epiphyses of long bones

FEMUR




HEMATOPOIESIS—pp 421- 422¹² (428- 429)¹³Vander

Copyright © The McGraw-Hill Companies, Inc. Permission required for reproduction or display.



**Injection of
Bone Marrow
Stem cells
can
reconstitute
ALL
hematopoietic
Cell Types**

Red Cell Precursors Proliferation



Divison and Differentiation




3 – 5 days

24 hours

Reticulocyte → RBC

Red Cell Precursors Differentiation





1. Decrease in size

2. Loss of nucleus

3. Accumulation of Hb

RETICULOCYTES



**Normal
Reticulocyte
Count < 1 %**

**(reflects the amount
of effective
erythropoiesis in
bone marrow)**

Factors determining # of RBCs

1. O_2 requirements
2. O_2 availability

Variations in RBC counts at different altitudes

ALTITUDE (1000's feet)	pO₂ (mmHg)	RBC (x 10⁶/μL)
0.7	150	4.5
4.4	120	5.2
12.0	100	6.8
15.6	90	7.8
18.2	85	8.3


ERYTHROPOIETIN

A glycoprotein hormone/cytokine produced largely by the kidney


Stimulus for its release is **Hypoxia** (which may result from decreased RBC count, or decreased availability of O₂ to blood, or increased tissue demand for O₂)

It has been purified, sequenced, gene has been cloned, and **EPO** has been produced by recombinant DNA technology


REGULATION OF ERYTHROPOIESIS



REGULATION OF ERYTHROPOIESIS



REGULATION OF ERYTHROPOIESIS



Regulation of Erythropoiesis

Erythropoietin, released from the kidney in presence of hypoxia, stimulates the bone marrow to produce more RBCs

Severe accidental hemorrhage



Less **Hb** available for **O₂** transport



Reduced supply of **O₂** to kidneys



↑ production & release of **erythropoietin**



↑ production of erythrocyte precursors in bone marrow



↑ discharge of young erythrocytes in blood





More **Hb** for **O₂** transport

Negative feedback loop


pp 8-9¹²;
8-9¹³

Vander

ERYTHROPOIETIN ACTION



HORMONAL EFFECTS ON **ERYTHROPOIETIN**



ESTROGEN has the opposite effects

Destruction of **RBCs**


Life Span of **RBCs** **120 days**

(during that time, each RBC travels the equivalent of 300 miles!)


NOTHING prolongs RBC lifespan!

Old **RBCs** are recognized as such and are removed from the circulation by a system of highly phagocytic cells known as **MACROPHAGES**


Phagocytosis of **old RBC** by Macrophage



Phagocytosis of **old RBC** by Macrophage




RBC membrane “digested”, contents released



JAUNDICE (Icterus)

1. Excessive Hemolysis



120d

MACROPHAGE

Hb

Heme

Bilirubin

1mg/dL

LIVER

2. Hepatic Damage

3. Bile Duct
Obstruction

Intestinal
tract

Bone
Marrow

NORMAL DYNAMICS FOR RBCs

PRODUCTION = DESTRUCTION

ABNORMAL DYNAMICS


PRODUCTION > DESTRUCTION  **POLYCYTHEMIA**

PRODUCTION < DESTRUCTION  **ANEMIA**


Clinical Indices

- Number of **RBCs**
- Amount of **Hb**
- Hematocrit


HEMATOCRIT



That **percentage** of Blood Volume occupied by **Red Blood Cells**




Normal



**Fluid Retention ?
Anemia**



Polycythemia Dehydration ?



POLYCYTHEMIA

p.420¹²; 431¹³ Vander

Polycythemia:

>18g% Hb

> 6 x 10⁶ RBC/uL

Normal:

16 g%

5-5.5 x 10⁶ RBC/uL

Relative - due to ↓ plasma volume

Absolute }
1. Physiological
2. Pathological

Physiological Polycythemia

(secondary to \uparrow O₂ needs or \downarrow O₂ availability)

- at high altitudes
- increased physical activity
- chronic lung disease
- heavy smoking

Pathological Polycythemia

- Tumours of Cells producing **Erythropoietin**
- **Unregulated Production by Bone Marrow**

Polycythemia vera - $7-8 \times 10^6$ RBC/uL

- Ht ~70%

What is the problem in Polycythemia?


↑ blood viscosity

Sluggish blood flow → **blood clots**

Decrease in the oxygen-carrying capacity of blood

1. RBC count ↓

< $4 \times 10^6/\mu\text{L}$




< $3.2 \times 10^6/\mu\text{L}$




2. Hb content ↓

< 11g%



< 9g%



Classification of Anemias

MORPHOLOGIC

1. MICROCYTIC

(<80u³)

NORMOCYTIC

(80-94u³)

MACROCYTIC

(>94u³)


2. NORMOCHROMIC

(~33%)


HYPOCHROMIC

(<33%)

ANEMIAS




NORMOCYTIC



MACROCYTIC

MICROCYTIC



NORMOCHROMIC

HYPOCHROMIC

Classification of Anemias

ETIOLOGIC

1. Diminished Production
2. Ineffective Maturation
3. Increased Destruction

Etiologic Classification of Anemia

1. Diminished Production

- (i) abnormal site
- (ii) abnormal stimulus
- (iii) inadequate raw materials

re (i) **APLASTIC (HYPOPLASTIC) ANEMIA**

ETIOLOGY : a. unknown

b. exposure to radiation

c. chemicals or drugs

CLASSIFICATION: **Normocytic, Normochromic**

re (ii) **STIMULATION FAILURE**

ETIOLOGY: renal disease


CLASSIFICATION: **Normocytic, Normochromic**

re (iii) inadequate raw materials

IRON DEFICIENCY ANEMIA (most common type)

ETIOLOGY: (i) ↑ requirements (infancy, adolescence, pregnancy)


(ii) inadequate supplies due to



CLASSIFICATION: Microcytic, Hypochromic

IRON

Total Amount in Body



Daily Intake in Diet : ~15-20 mg


Daily absorption from gut (depending on

need by body): ~1mg ♂

~2mg ♀

Normal erythropoiesis requires **25 mg Fe/d**


Normal RBC destruction \longrightarrow **25 mg Fe/d**
(**1mg/d lost**
24 mg/d recycled)

 require 1mg/d
 require 2mg/d } **WHY?**

1g **Hb** contains 3.5 mg **Fe**

15g **Hb**/100 ml of blood \longrightarrow **~50 mg Fe**

Menstrual loss ~ 50 ml blood/month

Therefore, lose **~ 25 mg Fe/month**
 + 28 mg Fe/month (cf.  1mg/d)

~ 50 mg/month or 2 mg/d

Classification of Anemias

ETIOLOGIC

1. Diminished Production

2. Ineffective Maturation ←

3. Increased Destruction ←

2. INEFFECTIVE MATURATION (Maturation Failure Anemia)

ETIOLOGY: deficiencies of Vitamin B12 and Folic Acid
(Both are required for normal synthesis of DNA)

CLASSIFICATION: Macrocytic, Normochromic

(i) Vitamin B₁₂

(usually failure to absorb)

(ii) Folic Acid

(usually dietary absence, overcooking vegetables)


Vitamin B12 Absorption

Intrinsic Factor Deficiency



Pernicious Anemia

ileum →



3. SURVIVAL DISORDERS

(Hemolytic Anemias – may be accompanied by jaundice)

ETIOLOGY: (i) Congenital

(ii) Acquired

- re (i) a) Abnormal Membrane Structure (e.g., hereditary spherocytosis)
(less flexible, more fragile)
- b) Abnormal Enzyme Systems
(abnormal metabolism)
- c) Abnormal **Hb** structure (e.g., sickle cell anemia)
(e.g., Thalassemia – deficient synthesis of globin amino acid chains)
- re (ii) a) **Toxins**
- b) **Drugs**
- c) **Antibodies**

LOSS OF BLOOD - Hemorrhage

a) external



b) internal (into tissues)




**HEMATOMA = accumulation
of blood in tissues**

ARREST of BLEEDING- Hemostasis

HEMOSTASIS - The arrest of bleeding following vascular injury


A number of interacting, overlapping mechanisms:



HEMOSTASIS



Vascular Injury



Vasoconstriction




Platelet Plug
Formation




Blood Clot
Formation

(i) Vascular Response



Vasoconstriction



(ii) Platelet Response (white thrombus)



Platelet Structure



~ 2-4 um diameter

NO nucleus


Many granules – factors for vasoconstriction, platelet aggregation, clotting, growth, etc..

Many filaments, microtubules, mitochondria, sER

~250,000/uL

Life Span: 7-10d


Platelet Production




Thrombopoietin
(mostly from liver)

Platelet Plug Formation

1. Adhesion
2. Activation and release of cytokines
3. Aggregation
4. Consolidation




Platelet Plug Formation




Exposed collagen binds & activates platelets

Platelet Plug Formation



Platelet Plug Formation



Platelet factors also promote coagulation scheme

Platelet Functions

- (a) Release vasoconstricting agents
- (b) Form Platelet Plug
- (c) Release Clotting Factors
- (d) Participate in Clot Retraction
- (e) Promote Maintenance of Endothelial Integrity

ABNORMAL PRIMARY HEMOSTATIC RESPONSE → **Prolonged Bleeding**

1. Failure of Blood Vessel to constrict

2. Platelet deficiencies

a) Numerical < 75,000/uL


b) Functional → congenital

→ acquired

Aspirin (in small doses) inhibits synthesis and release of TXA2

→ (Drugs, Toxins, Antibodies)

Blood Clot = THROMBUS



10 — ELECTRON MICROSCOPE INST. INC. DEAN AIR TEL 17-41-04-207
Mag. 10,000 X 10000 PAH BV 1.0000 200 PA 20 200 10000000

Clot Formation is a function of PLASMA (RBCs are “innocent bystanders”, NOT necessary for the process!!!)

CLOTTING: initiated by injury to blood vessel wall, results in sequential activation and interaction of a group of plasma proteins or clotting factors (some acting as enzymes, others as co-factors), in the presence of Ca⁺⁺ and some phospholipid agents

3 STAGES:


- 1
- 2
- 3

Protein factors named as Roman Numerals I - XIII (in order in which they were discovered)

3 – 6 mins INTRINSIC PATHWAY

15 – 20 secs EXTRINSIC PATHWAY

Tissue Factors (prot & phospholipid) released from damaged cells



(3-6 minutes)

(15-20 seconds)

INTRINSIC PATHWAY

EXTRINSIC PATHWAY

Damage to blood vessel

Damage to tissue outside vessel

Interacting plasma factors + Ca⁺⁺ + PF₃

Interacting plasma factors + Ca⁺⁺ + Tissue Phospholipid

PRO THROMBINASE

Prothrombin

Thrombin

Fibrinogen

Fibrin

Blood Clot

Cross-linking

INTRINSIC PATHWAY

(3-6 minutes)

EXTRINSIC PATHWAY

(15-20 seconds)

The small amounts of **THROMBIN** generated rapidly by the **Extrinsic Scheme**, are sufficient to trigger its strongly positive feedback effects on the **Intrinsic Scheme** to generate larger quantities of **THROMBIN**

Clotting is kept in check by INHIBITORS (of platelet adhesion) and ANTICOAGULANTS (naturally occurring chemicals which block one or more of the reactions of the coagulation scheme).

Please read Vander pp. 425-426¹²; 437- 439¹³

ANTICOAGULANTS:

- Heparin and antithrombin III work together to block IX, X, XI, XII**
- Protein C inhibits Factors V and VIII**

FACTORS IN COAGULATION

Ca⁺⁺

PHOSPHOLIPID

PROTEIN PLASMA FACTORS

CLOTTING FACTOR DEFICIENCIES

CONGENITAL

**Hereditary
deficiencies of
(usually) a single
factor**

e.g. VIII (Hemophilia)


ACQUIRED

**Usually
multifactor
deficiencies (e.g.,
(i) liver disease**

**(ii) Vitamin K
deficiency**

**(Vit. K is cofactor in synthesis of
Prothrombin, VII, IX, X)**

Clot Retraction




Retraction depends on the presence of a contractile protein (thrombosthenin) released by platelets.

Clot Lysis (Fibrinolysis)

Intrinsic proactivators
e.g. Factor XIIa

Endothelial cell factors

Extrinsic proactivators
e.g. tissue factors



1. INHIBITORS of PLATELET ADHESION (e.g., aspirin)

2. ANTICOAGULANT DRUGS (interfere with clot formation)

(i) COUMARIN – blocks synthesis of functional Prothrombin, VII, IX, X

(ii) HEPARIN – promotes inhibition of THROMBIN activation and action

3. THROMBOLYTIC DRUGS (promote clot lysis)

(i) TISSUE PLASMINOGEN ACTIVATOR (t-PA)

(ii) STREPTOKINASE

Please read Vander p.427¹²; 438-439¹³